Entry Detail


General Information

Database ID:exR0100506
RNA Name:hsa-let-7f-1-3p
RNA Type:miRNA
Chromosome:chr9
Starnd:+
Coordinate:
Start Site(bp):94176409End Site(bp):94176430
External Links:hsa-let-7f-1-3p



Disease Information

Disease Name:Colorectal Cancer
Disease Category:Cancers
MeSH ID:D003110
Type:Neoplasms/Digestive System Neoplasms
Alias:Colonic Neoplasms//Colonic Neoplasm//Neoplasm, Colonic//Neoplasms, Colonic//Colon Neoplasms//Colon Neoplasm//Neoplasm, Colon//Neoplasms, Colon//Cancer of Colon//Colon Cancers//Cancer of the Colon//Colonic Cancer//Cancer, Colonic//Cancers, Colonic//Colonic Cancers//Colon Cancer//Cancer, Colon//Cancers, Colon



Expression Detail

GEO ID:GSE106817
Description:Integrated extracellular microRNA profiling for ovarian cancer screening
Experimental Design:Cancer vs Control
Case Disease Type:Benign Ovarian Disease
Case Disease SubType:NA
Case Sample:Colorectal Cancer
Control Sample:Non-Cancer
Number of Case:29
Number of Control:2759
Number of Samples:2788





Regulatory Relationship

mRNA targets:NA
miRNA targets:NA
circRNA targets:NA
lncRNA targets:NA
Display:N/A



Experiment Detail

GEO ID:GSE106817
Sample Source:Blood
Source Fraction:Serum
Platform:GPL21263
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:2535
Sample treatment protocol:NA
RNA Extract protocol:Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).
RNA library preparation protocol:miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.



Reference

PMID:30333487
Title:Integrated extracellular microRNA profiling for ovarian cancer screening
Author:Yokoi A, Matsuzaki J, Yamamoto Y, Yoneoka Y, Takahashi K, Shimizu H, Uehara T, Ishikawa M, Ikeda SI, Sonoda T, Kawauchi J, Takizawa S, Aoki Y, Niida S, Sakamoto H, Kato K, Kato T, Ochiya T
Journal:Nat Commun. 2018 Oct 17;9(1):4319.
Description:to develop an optimal detection method, we use microarrays to obtain comprehensive miRNA profiles from 4046 serum samples, including 428 patients with ovarian tumors.